Lamoureux v. Genesis Pharmacy Services Inc.

226 F.R.D. 154, 2004 U.S. Dist. LEXIS 27048, 2004 WL 3153231
CourtDistrict Court, D. Connecticut
DecidedJanuary 28, 2004
DocketCiv. No. 3:03CV1382CFDTPS
StatusPublished
Cited by10 cases

This text of 226 F.R.D. 154 (Lamoureux v. Genesis Pharmacy Services Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Connecticut primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Lamoureux v. Genesis Pharmacy Services Inc., 226 F.R.D. 154, 2004 U.S. Dist. LEXIS 27048, 2004 WL 3153231 (D. Conn. 2004).

Opinion

RULING ON DEFENDANTS MOTION TO COMPEL AND FOR EXPENSES

SMITH, United States Magistrate Judge.

The plaintiffs, Gary A. Lamoureux, Richard A. Terwilliger, (together the “Individual Plaintiffs”) and World Wide Medical Technologies, LLC (“WWMT”), commenced this action against the defendant, Genesis Pharmacy Services Inc., d/b/a Custom Care Pharmacy (“Genesis”), alleging inter alia, patent infringement in violation of 35 U.S.C. § 271, false designation of origin/false advertising in violation of Section 43(a) of the Lanham Act, 15 U.S.C. § 1125(a), breach of contract, and unfair trade practices within the meaning of section 42-110b of the Connecticut General Statutes. (Compl. KK 21-42). Pending before the court is the defendant’s Motion to Compel and for expenses (Dkt. #48). As explained below, the defendant’s motion, in all respects, is GRANTED.

Background

This case centers on a patent jointly held by the Individual Plaintiffs known familiarly as the “760 Patent” which describes a “PreLoaded Needle Assembly” that is used to treat cancer by implanting therapeutic elements (radioactive “seeds”) into the body. (Compl. K 6, Ex. A). Essentially, the needles were “pre-loaded” with these elements which “reduces preparation time as well as personal exposure to the radioactive seeds.” (Id. at Ex. A at 2). Moreover, the invention “exactly locates the first seed a repeatable and known distance from the distal end of the cannula in each needle used thus improving the accuracy of placing the radioactive seeds in the body.” (Id.).

In pre-loading these needles, “it is necessary to plug the exit end of the needle with some material so that the seeds and spacers will not fall out (and also to prevent body fluids from entering the needle bore when it is inserted into the prostate).” (Id. K 9). Where previously, the prior art required that oncologists or physicists use less ideal plugs such as “bone wax”, the patent describes a “pre-plugged” needle “in which the exit bore contains within it a ‘plug’ of any suitable biocompatible material, which is placed at a predetermined distance from the needle exit.” (Id. K11, Ex. A at 2).

Principally, the use of a plug which is placed at a defined, predetermined distance within the needle bore end — in contrast to the prior art practice of plugging the needle end in a manner which results in a variable and uncontrolled extent of plugging material within the needle bore end area^ — means that the desired predetermined placement of seeds and spacers within the needle to produce a specific implantation array and pattern of seeds in the prostate can be achieved with exactitude rather than the imprecision occasioned by the prior art variable degree of incursion of a plugging material into the needle bore.

(Id. K12). Essentially, “pre-plugged” needles offer greater precision than the prior art.

In September of 2001, the parties entered into an agreement whereby inter alia WWMT would sell to Genesis its brand of pre-plugged needles. (Id. K14). However, when circumstances allegedly revealed that Genesis “was either using pre-plugged needles from another source for preparing the Readi-Load™ system of pre-plugged needles and/or that [Genesis] was using WWMT’s pre-plugged needles but assembling and distributing pre-plugged, loaded needles and kits without accounting to WWMT, all in contravention of the agreement,” WWMT terminated the relationship. (Id. KK 15-16).

The plaintiffs complain that they are owed money on the original agreement, that Genesis continues, without authorization or license from WWMT, loading seeds into pre-plugged needles either manufactured by it or obtained from others, that it is advertising the same on its website and elsewhere and that, in so doing it is using a depiction of WWMT’s own Seed-Lock™ pre-plugged needles and Readi-Load™ system, and that it makes [157]*157false and or misleading representations to others regarding the same. (Id. Hit 17-20).

With its Answer, Genesis has asserted several affirmative defenses, including that the 760 Patent is not valid under 35 U.S.C. §§ 102,103, and/or 112, that it is not enforceable due to the plaintiffs’ misuse of the patent, and that its use does not infringe upon the patent. (Ans. at 7-8). In addition, Genesis has filed several counterclaims seeking a declaratory judgment of non-infringement and invalidity, tortious interference, unfair trade practices, breach of contract, breach of implied contract, and unjust enrichment. (Ans. at 8-17).

Three discovery requests form the basis of the present motion: two interrogatories (Interrogatories No. 1 and 14) and one request for admission (Request for Admission No. 82). Interrogatory No. 1 requests that the plaintiffs “state the earliest dates upon which each invention claimed in the patent-in-suit is contended ... to have been conceived and reduced to practice, and identify all facts, documents and witnesses which support each such date.” (D.’s Mem. Supp. Mot., 9/14/04, at 7, Ex. A at 3-4). The plaintiffs responded that

[tjhis interrogatory is objected to as irrelevant and not reasonably calculated to lead to the discovery of admissible evidence. To date, defendant has not made known its defenses, if any, based upon prior art, nor has defendant identified any alleged prior art it is relying upon in connection with those defenses. The conception and reduction to practice dates for the invention of the ’760 Patent have relevance only insofar as determining whether an item of alleged prior art relied upon by defendant under either 35 U.S.C. §§ 102(a), 102(e) or 102(g) is in fact prior art. Until such time as defendant makes explicit its assertions in this respect, and until such time as Lamoureux and his co-plaintiffs then elect to allege a date of invention earlier than any such alleged prior art so as to “swear behind” it, the subject matters inquired of are irrelevant.

(Id.). However, in an attempt to “compromise”, the plaintiffs supplemented this response accordingly:

This interrogatory is objected to as irrelevant and not reasonably calculated to lead to the discovery of admissible evidence. To date, defendant has not made known its defenses, if any, based upon prior art, nor has defendant identified any alleged prior art it is relying upon in connection with those defenses. The conception and reduction to practice dates for the invention of the ’760 Patent have relevance only insofar as determining whether an item of alleged prior art relied upon by defendant under 35 U.S.C. §§ 102(a), 102(e) or 102(g) is in fact prior art. Subject to these and the general objections, and without waiver thereof, Plaintiff Lamoureux states that he will provide the date of conception and reduction to practice, and documents evidencing the same, after the entry of a suitable protective order governing the disclosure of confidential information.

(Id. at 9, Ex. 7 at 1, Ex. D at 3-4,).

Interrogatory No.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cleer LLC v. Crystal Stranger
D. Connecticut, 2026
Wolterstorff v. Quiros
D. Connecticut, 2025
Mercer v. Schriro
D. Connecticut, 2022
Anaheim Gardens v. United States
125 Fed. Cl. 88 (Federal Claims, 2016)
Lakeland Partners, L.L.C. v. United States
88 Fed. Cl. 124 (Federal Claims, 2009)
Ford Motor Co. v. United States
84 Fed. Cl. 168 (Federal Claims, 2008)
Wagner v. St. Paul Fire & Marine Insurance
238 F.R.D. 418 (N.D. West Virginia, 2006)
Pacific Gas & Electric Co. v. United States
69 Fed. Cl. 323 (Federal Claims, 2005)

Cite This Page — Counsel Stack

Bluebook (online)
226 F.R.D. 154, 2004 U.S. Dist. LEXIS 27048, 2004 WL 3153231, Counsel Stack Legal Research, https://law.counselstack.com/opinion/lamoureux-v-genesis-pharmacy-services-inc-ctd-2004.